C The Signs Secures £3.1m Series B For AI Cancer Detection Platform

London-based clinical technology firm C The Signs Limited has finalized a £3.1m Series B funding round, according to recent regulatory filings. The investment brings the company to an estimated post-money valuation of £26.2m. This capital injection follows a period of sustained expansion for the firm as it continues to integrate its artificial intelligence diagnostic tools into primary care settings across the United Kingdom.

The funding round was formalized through a share allotment dated 19 December 2025, with the corresponding documentation filed on 5 March 2026. While the specific list of participating investors in this particular tranche was not named in the recent filing, the company has historically attracted support from prominent venture capital firms such as MMC Ventures. This Series B round represents a significant milestone in the company's valuation trajectory, reflecting its transition from a specialized diagnostic tool to an integrated health system platform.

C The Signs was founded in March 2017 by Dr Bhavagaya Bakshi and Dr Miles Payling. The company was established to address a critical bottleneck in the healthcare system: the early detection of cancer. Late-stage diagnosis is widely recognized as a primary factor in poor patient outcomes and increased treatment costs for the National Health Service. The founders, both medical professionals, developed the platform to assist General Practitioners in navigating the complex landscape of cancer symptoms and referral pathways.

The core technology consists of an AI-powered clinical decision support tool that integrates with existing electronic health record systems. By analyzing patient data in real time, the platform cross-references symptoms, medical history, and specific risk factors against thousands of clinical guidelines. It then recommends the most appropriate diagnostic tests or specialist referrals. The target market for the company includes individual GP practices, large-scale healthcare providers, and Integrated Care Boards that are looking to improve cancer survival rates and optimize referral efficiency.

Since its incorporation in 2017, the company has grown its operational capacity significantly. C The Signs currently employs approximately 40 staff members, including clinical safety experts, data scientists, and technical integration specialists. While the firm remains in a growth phase, its platform is now utilized by thousands of healthcare professionals across the UK. Financial metrics indicate that the company has focused on steady expansion within the NHS framework while also exploring opportunities in international markets, including the United States.

The current funding landscape for UK health tech remains focused on companies that provide demonstrable clinical value and cost-savings. Diagnostic AI has become a prioritized sector within the London tech ecosystem, as health systems seek technology to alleviate the pressure on primary care services. The £3.1m raised by C The Signs is indicative of a broader trend where mid-stage companies are opting for strategic, targeted rounds to support specific operational goals rather than pursuing larger, highly dilutive capital raises.

In the context of the UK market, C The Signs operates in a competitive but high-demand niche. The government's long-term health strategy places a heavy emphasis on early cancer diagnosis, with a goal of diagnosing 75 percent of cancers at stage one or two by 2028. Tools that can automate the screening of clinical guidelines and provide immediate decision support at the point of care are essential to meeting these targets.

The company plans to use the proceeds from this Series B round to further refine its machine learning models and expand its data sets. As more longitudinal patient data becomes available, the AI is expected to become increasingly accurate at identifying subtle patterns that may precede a formal cancer diagnosis. Additionally, the capital will support the company's efforts to navigate the complex procurement cycles associated with large-scale health systems both in the UK and abroad.

This latest valuation of £26.2m places C The Signs among the established players in the London health tech sector. By securing this funding, the company maintains its runway to continue clinical validation and commercial deployment, ensuring that its AI-driven approach to cancer detection remains at the forefront of primary care innovation.